At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CPRX Catalyst Pharmaceuticals
Halted 07-31 16:00:00 EDT
31.49
+0.00
0.00%
High31.49Low31.49Vol0.00
Open31.49D1 Closing31.49Amplitude0.00%
Mkt Cap3.85BTradable Cap3.62BTotal Shares122.12M
T/O0.00T/O Rate0.00%Tradable Shares115.02M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Deals of the Day-mergers and Acquisitions
Reuters  ·  07-16
Deals of the Day-mergers and Acquisitions
Catalyst Pharmaceuticals Shares Face NASDAQ Suspension as Company Moves to Delist After Merger
Reuters  ·  07-16
Catalyst Pharmaceuticals Shares Face NASDAQ Suspension as Company Moves to Delist After Merger
Italy's Angelini Pharma Completes $4.1 Billion State-backed Takeover of Catalyst
Reuters  ·  07-16
Italy's Angelini Pharma Completes $4.1 Billion State-backed Takeover of Catalyst
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
THOMSON REUTERS  ·  07-16
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
Sector Update: Energy
MT Newswires Live  ·  07-10
Sector Update: Energy
Solaris Energy Rises on S&P Smallcap Inclusion
Reuters  ·  07-10
Solaris Energy Rises on S&P Smallcap Inclusion
Solaris to replace Catalyst Pharmaceuticals in the S&P 600 at open on 7/15
TIPRANKS  ·  07-10
Solaris to replace Catalyst Pharmaceuticals in the S&P 600 at open on 7/15
S&P Dow Jones Indices Says Solaris Energy Infrastructure Inc. Will Replace Catalyst Pharmaceuticals Inc. in the S&P Smallcap 600
THOMSON REUTERS  ·  07-10
S&P Dow Jones Indices Says Solaris Energy Infrastructure Inc. Will Replace Catalyst Pharmaceuticals Inc. in the S&P Smallcap 600
Catalyst Pharma (CPRX) Receives a Buy from H.C. Wainwright
TIPRANKS  ·  07-09
Catalyst Pharma (CPRX) Receives a Buy from H.C. Wainwright
Catalyst Pharmaceuticals Shareholders Vote to Adopt Angelini Pharma Merger Agreement at Special Meeting
Reuters  ·  07-09
Catalyst Pharmaceuticals Shareholders Vote to Adopt Angelini Pharma Merger Agreement at Special Meeting
Catalyst and Angelini Pharma Merger Receives Early Termination of Waiting Period Under HSR Act
MT Newswires Live  ·  06-24
Catalyst and Angelini Pharma Merger Receives Early Termination of Waiting Period Under HSR Act
Catalyst Pharma says FTC grants early HSR clearance for Angelini deal
Reuters  ·  06-24
Catalyst Pharma says FTC grants early HSR clearance for Angelini deal
Catalyst Pharmaceuticals Sets July 2026 Vote on $31.50-per-Share Angelini Pharma Buyout
TIPRANKS  ·  06-09
Catalyst Pharmaceuticals Sets July 2026 Vote on $31.50-per-Share Angelini Pharma Buyout
Catalyst Pharmaceuticals Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones  ·  05-29
Catalyst Pharmaceuticals Cut to Neutral From Buy by HC Wainwright & Co.
Catalyst Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
TIPRANKS  ·  05-29
Catalyst Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
CVC, GBL launch €10.7 billion bid for Italian drugmaker Recordati
Reuters  ·  05-22
CVC, GBL launch €10.7 billion bid for Italian drugmaker Recordati
Angelini Buyout And Firdapse Settlement Reframe Catalyst Pharmaceuticals Story
Simply Wall St.  ·  05-17
Angelini Buyout And Firdapse Settlement Reframe Catalyst Pharmaceuticals Story
Catalyst Pharmaceuticals reports Q1 non-GAAP EPS 79c, consensus 64c
TIPRANKS  ·  05-12
Catalyst Pharmaceuticals reports Q1 non-GAAP EPS 79c, consensus 64c
Catalyst Pharmaceuticals not providing forward-looking guidance
TIPRANKS  ·  05-12
Catalyst Pharmaceuticals not providing forward-looking guidance
Catalyst Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-12
Catalyst Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Introduction

Company Name.
Catalyst Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Issue price:
--